Novavax and Israel announced advance purchase agreement for supply of COVID-19 vaccine
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
On Jan. 28, 2022, the WHO announced that COVID-19 information had reached 1,292,209 people through Viamoï¾’s 3-2-1 Platform…
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
On Jan. 27, 2022, NIAID announced that a clinical trial found that the combination of remdesivir plus a…
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Jan. 26, 2022, the NIH announced that adults who had previously received a full regimen of any…
On Jan. 26, 2022, scientists at Tufts and Harvard Universityï¾’s Wyss Institute reported they were able to trigger…
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
On Jan. 25. 2022, a report published in PNAS provided strong evidence of extensive SARS-CoV-2 infection of white-tailed…
On Jan. 25, 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety,…
On Jan. 25, 2022, the U.S. Department of Agricultureï¾’s National Veterinary Services Laboratories announced a study with zoos…
On Jan. 25, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
On Jan. 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
The Evolution of CRISPR illustrates its climb out of the primordial ocean on the backs of eukaryotic cells…
On Jan. 24, 2022, Pfizer and BioNTech announced the publication of new results from two laboratory studies demonstrating…
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
On Jan. 24, 2022, Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that it had leveraged its novel…
On Jan. 24, 2022, the University of Oxford announced that a third booster dose of either the ChAdOx1…
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
On Jan. 20, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration had granted expedited approval…
On Jan. 20, 2022, the National Institutes of Health announced it was awarding $170 million over five years,…
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
On Jan. 18, 2021, Humanigen announced a peer-reviewed publication in the Journal of Medical Economics citing the clinical…
On Jan. 18, 2022, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
On Jan. 17, 2022, Our Future Health announced the launch of UKï¾’s largest ever health research programme to…
On Jan. 16, 2022, the WHO announced that it had shipped 1.1 million COVID-19 vaccines to Rwanda on…
On Jan. 14, 2022, the WHO announced that it had recommended two new drugs for COVID-19, providing yet…